Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Tedizolid was approved for complicated skin and skin-structure infections (cSSSI) not ABSSSI. But just for entertainment...It is also a spin off of Linezolid both are oxazolidinone class of drugs which has already been on the market for 14 years, good look with no resistance now. Tedizolid is a 7 day oral tablet which is good because I am not going to the doctor for 7 days because of a scratch on my knee. Lets say we are in a magical world where Tedizolid is approved for ABSSSI medically speaking compliance would work better with a one time IV of Brilacidin at the initial visit at the doctors office then sending someone home with pills to take for 7 days.

Jerry lets not confuse our 2a's with our 2b's there was no 3 day dosing in 2a only 7 day. So any reference to 3 day would have to be 2b. From the 2a the sustained response at day 28 for low, medium and high dose were 95.7, 89.6 and 95.6 respectively for Brilacidin with Dapto at 98%.

http://files.shareholder.com/downloads/ABEA-4ITCYZ/1997024712x0x611205/FEA66C67-D02F-4FF2-B230-AA711F46ED7F/PMX-30063_Antibiotic_Fact_Sheet_Nov_2012_.pdf

As far as the cell membrane I would invite to read publication from my colleagues at the University of Washington.


Congress is passing laws and the President is signing executive orders to desperately promoting antibiotic development. They must have missed your memo on heated up or the already crowded antibiotic market.